Skip to main content

Advertisement

SpringerLink
Log in

Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Many studies investigated the relationship between matrix metalloproteinase 2 (MMP-2) overexpression and survival in patients with colorectal cancer (CRC), but yielded inconsistent results. To derive a more precise estimate of the prognostic significance of MMP-2 overexpression, we reviewed published studies and carried out a meta-analysis. Eligible articles were identified for the period up to March 2012 in electronic databases. To evaluate the correlation between MMP-2 overexpression and the prognosis in CRC, pooled hazard ratio (HR) and its 95 % confidence interval (95 % CI) for poorer overall and progression-free survival were appropriately derived from fixed-effects or random-effects models using standard meta-analysis techniques. Thirteen studies with a total of 1,919 CRC patients stratifying overall survival (OS) and/or progression-free survival in CRC patients by MMP-2 expression status were eligible for analysis. Ten studies investigated the OS in a total of 1,612 cases with CRC, and five studies investigated the progression-free survival in a total of 508 patients CRC. The combined HR estimate for OS and progression-free survival was 1.74 (95 % CI, 1.34–2.26) and 1.35 (95 % CI, 1.07–1.80), respectively. Both subgroup analyses and sensitivity analysis further identified the prognostic role of MMP-2 overexpression in patients with CRC. There was no evidence for publication bias. In conclusion, MMP-2 overexpression is associated with poorer overall and progression-free survival in patients with CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047

    Article  PubMed  Google Scholar 

  2. Lieberman DA (2009) Clinical practice. Screening for colorectal cancer. N Engl J Med 361:1179–1187

    Article  PubMed  CAS  Google Scholar 

  3. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101–117

    Article  PubMed  CAS  Google Scholar 

  4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:163–176

    Article  Google Scholar 

  5. Escaff S, Fernandez JM, Gonzalez LO et al (2011) Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol 137:551–555

    Article  PubMed  CAS  Google Scholar 

  6. Leeman MF, Curran S, Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201:528–534

    Article  PubMed  CAS  Google Scholar 

  7. Langers AM, Verspaget HW, Hawinkels LJ et al (2012) MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer. doi:10.1038/bjc.2012.80

    PubMed  Google Scholar 

  8. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012

    Article  PubMed  CAS  Google Scholar 

  9. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  PubMed  CAS  Google Scholar 

  10. Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16

    Article  PubMed  Google Scholar 

  11. Maxwell L, Santesso N, Tugwell PS et al (2006) Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol 33:2304–2311

    PubMed  Google Scholar 

  12. Millett GA, Flores SA, Marks G et al (2008) Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 300:1674–1684

    Article  PubMed  CAS  Google Scholar 

  13. Wells G, Shea B, O’Connell D et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Ottawa Health Research Institute Web site. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 26 June 2012

  14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  16. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  17. Thompson SG, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573

    Article  PubMed  Google Scholar 

  18. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17

    Google Scholar 

  19. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  20. Hilska M, Roberts PJ, Collan YU et al (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714–723

    Article  PubMed  CAS  Google Scholar 

  21. Li M, Li JY, Zhao AL et al (2007) Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1. Dis Colon Rectum 50:1887–1898

    Article  PubMed  Google Scholar 

  22. Sundov Z, Tomic S, Vilovic K et al (2008) Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke’s B colon cancer. Croat Med J 49:636–642

    Article  PubMed  Google Scholar 

  23. Zhou ZG, Wu XJ, Li LR et al (2011) A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients. Chin Med J (Engl) 124:2132–2135

    CAS  Google Scholar 

  24. Langers AM, Sier CF, Hawinkels LJ et al (2008) MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 98:1820–1823

    Article  PubMed  CAS  Google Scholar 

  25. Unsal D, Akyurek N, Uner A et al (2008) Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 31:55–63

    Article  PubMed  CAS  Google Scholar 

  26. Dong W, Li H, Zhang Y et al (2011) Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai) 43:840–848

    Article  CAS  Google Scholar 

  27. Cho YB, Lee WY, Song SY et al (2007) Matrix metalloproteinase-9 activity is associated with poor prognosis in T3–T4 node-negative colorectal cancer. Hum Pathol 38:1603–1610

    Article  PubMed  CAS  Google Scholar 

  28. Hong SW, Kang YK, Lee B et al (2011) Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 27:133–139

    Article  PubMed  Google Scholar 

  29. Lu GJ, Cao XC, Lu FL (2009) The correlation between of matrixmetalloproteinase2 and rectal cancer. J Int Oncol 36:554–557

    CAS  Google Scholar 

  30. Peng ZH, Wan DS, Li LR et al (2011) Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology 58:369–376

    PubMed  CAS  Google Scholar 

  31. Schwandner O, Schlamp A, Broll R et al (2007) Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 22:127–136

    Article  PubMed  CAS  Google Scholar 

  32. Gonzalez LO, Gonzalez-Reyes S, Junquera S et al (2010) Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol 136:1313–1321

    Article  PubMed  CAS  Google Scholar 

  33. Uhlmann ME, Georgieva M, Sill M et al (2012) Prognostic value of tumor progression-related gene expression in colorectal cancer patients. J Cancer Res Clin Oncol. doi:10.1007/s00432-012-1238-7

    PubMed  Google Scholar 

  34. Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149

    PubMed  CAS  Google Scholar 

  35. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  PubMed  CAS  Google Scholar 

  36. Watanabe T, Kobunai T, Yamamoto Y et al (2012) Chromosomal instability (CIN) phenotype, CIN high or CIN low predicts survival for colorectal cancer. J Clin Oncol. doi:10.1200/JCO.2011.38.6490

    PubMed  Google Scholar 

  37. Hahn N, Heiden M, Seitz R et al (2012) Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol 138:695–703

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no competing financial interests.

Author information

Authors and Affiliations

  1. Department of Pathology, Harbin Medical University-Daqing Section, Daqing, 163319, Heilongjiang, China

    Mumu Shi

  2. Biopharmaceutical Institute, The Heilongjiang Academy of Medical Sciences, Harbin, 150081, Heilongjiang, China

    Mumu Shi, Jingwen Mu & Changwei Ji

  3. Geriatric Ward, The Fifth Affiliated Hospital of Harbin Medical University, Daqing, 163319, Heilongjiang, China

    Bo Yu

  4. Clinical Laboratory, The Daqing Oil Field General Hospital, Daqing, 163001, Heilongjiang, China

    Hongguo Gao

  5. Department of Anatomy, Harbin Medical University-Daqing Section, Daqing, 163319, Heilongjiang, China

    Jingwen Mu & Changwei Ji

Authors
  1. Mumu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongguo Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingwen Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Changwei Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Changwei Ji.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shi, M., Yu, B., Gao, H. et al. Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis. Mol Biol Rep 40, 617–623 (2013). https://doi.org/10.1007/s11033-012-2100-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-2100-3

Keywords

Search

Navigation